Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Metabolism
  4. Volume 25, Issue 10
  5. Article
Volume 25, Issue 10
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Sickle cell disease (SCD) is a hereditary blood disorder resulting from the production of distorted hemoglobin molecules that cause red blood cells to adopt a sickle or crescent-like shape. This disease affects millions of people, particularly those of African, Mediterranean, Middle Eastern, or South Asian descent. In recent years, however, advancements in the CRISPR-Cas9 gene-editing systems have surged. CRISPR stands for clustered regularly interspaced short palindromic repeats, referring to a specific organization of short, partially repeated DNA sequences in prokaryotic genomes. The CRISPR-Cas9 technique is based on the type II CRISPR system of bacteria and involves the Cas9 nuclease, which is targeted to a particular genome section with the help of single-guide RNA. Initially used for random mutations and small sequence alterations, genome editing methods have advanced to achieve large-scale DNA segment manipulation. The BE and PE-type CRISPR-Cas9 genome editing variants provide new therapeutic options for genetic disorders, improving patients' prognosis. Curative gene editing using CRISPR-Cas9 technology to correct HBB gene mutations that cause SCD represents a revolutionary therapeutic development. These advances bring new hope to patients with previously untreatable diseases, potentially offering a future where genetic disorders can be addressed at their roots. A major objective of CRISPR technology is to enhance its precision and speed, both critical for effective gene editing. This review focuses on molecular mechanisms of CRISPR-Cas9 technology, CRISPR- Cas9-based approaches for HBB gene modification, clinical trials, patients with sickle cell disease, and advances in CRISPR technology for sickle cell disease.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002356293250225094826
2024-12-01
2025-06-20

  • From This Site

    /content/journals/cdm/10.2174/0113892002356293250225094826
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Abdel-HadiL. Ventura CarmenateY. Castillo-AlemanY.M. SheikhS. ZakariaA. PhillipsJ. Treatment of sickle cell disease - Options and perspective.Am. J. Blood Res.2023132617037214647
     [Google Scholar]
  2. OmoregieG. Public health and social implications for management and control of scd in developing countries.SCD in Sub-Saharan AfricaRoutledge2024112127
     [Google Scholar]
  3. ColombattiR. HegemannI. MediciM. BirkegårdC. Systematic literature review shows gaps in data on global prevalence and birth prevalence of sickle cell disease and sickle cell trait: Call for action to scale up and harmonize data collection.J. Clin. Med.20231217553810.3390/jcm1217553837685604
     [Google Scholar]
  4. FrancoE. KarkoskaK.A. McGannP.T. Inherited disorders of hemoglobin: A review of old and new diagnostic methods.Blood Cells Mol. Dis.202410410275810.1016/j.bcmd.2023.10275837246072
     [Google Scholar]
  5. AhmedS. IbrahimU. The roles of acute and chronic marrow dysfunctions in the aetiology of anaemia in SCD: Pathogenesis and management: marrow dysfunction in SCD.Orient J. Med.2024363-4
     [Google Scholar]
  6. GangerS. HaraleG. MajumdarP. Clustered regularly interspaced short palindromic repeats/CRISPR-associated (CRISPR/Cas) systems: Discovery, structure, classification, and general mechanism.CRISPR/Cas-Mediated Genome Editing in Plants.Apple Academic Press659710.1201/9781003331759‑4
     [Google Scholar]
  7. ShchaslyvyiA.Y. AntonenkoS.V. TesliukM.G. TelegeevG.D. Current state of human gene therapy: Approved products and vectors.Pharmaceuticals20231610141610.3390/ph1610141637895887
     [Google Scholar]
  8. SinghV. DharP.K. Genome engineering via CRISPR-Cas9 system.Academic Press2020
     [Google Scholar]
  9. KooninE.V. GootenbergJ.S. AbudayyehO.O. Discovery of diverse CRISPR-Cas systems and expansion of the genome engineering toolbox.Biochemistry202362243465348710.1021/acs.biochem.3c0015937192099
     [Google Scholar]
  10. LiuY. LiuW. WangB. Engineering CRISPR guide RNAs for programmable RNA sensors.Biochem. Soc. Trans.20235162061207010.1042/BST2022148637955062
     [Google Scholar]
  11. SharrarA. Arake de TaccaL. CollingwoodT. MeachamZ. RabukaD. Staples-AgerJ. SchelleM. Discovery and characterization of novel type V Cas12f nucleases with diverse protospacer adjacent motif preferences.CRISPR J.20236435035810.1089/crispr.2023.000637267210
     [Google Scholar]
  12. SinghS. ChaudharyR. DeshmukhR. TiwariS. Opportunities and challenges with CRISPR-Cas mediated homologous recombination based precise editing in plants and animals.Plant Mol. Biol.20231111-212010.1007/s11103‑022‑01321‑536315306
     [Google Scholar]
  13. LiZ. YouL. HermannA. BierE. Developmental progression of DNA double-strand break repair deciphered by a single-allele resolution mutation classifier.Nat. Commun.2024151262910.1038/s41467‑024‑46479‑238521791
     [Google Scholar]
  14. HazarikaG. A comprehensive exploration of restriction enzymes and their applications in molecular biology: A review.World J. Adv. Res. Rev.20242112399240410.30574/wjarr.2024.21.1.0269
     [Google Scholar]
  15. FrascarelliC. ZanettiN. NascaA. IzzoR. LampertiC. LamanteaE. LegatiA. GhezziD. Nanopore long-read next-generation sequencing for detection of mitochondrial DNA large-scale deletions.Front. Genet.202314108995610.3389/fgene.2023.108995637456669
     [Google Scholar]
  16. LiD.Y. LiL.Q. LiuJ.J.G. Nucleases in gene-editing technologies: Past and prologue.National Science Open2023252022006710.1360/nso/20220067
     [Google Scholar]
  17. JohnsonL.A. MartR.J. AllemannR.K. A photoresponsive homing endonuclease for programmed DNA cleavage.ACS Synth. Biol.202413119520510.1021/acssynbio.3c0042538061193
     [Google Scholar]
  18. ZhengY. LiY. ZhouK. LiT. VanDusenN.J. HuaY. Precise genome-editing in human diseases: Mechanisms, strategies and applications.Signal Transduct. Target. Ther.2024914710.1038/s41392‑024‑01750‑238409199
     [Google Scholar]
  19. SharmaK. GuptaS.S. Implications of CRISPR technology in biological systems.Biotechnological Advances for Microbiology, Molecular Biology, and NanotechnologApple Academic Press202224528210.1201/9781003161158‑12
     [Google Scholar]
  20. AlipanahiR. SafariL. KhanteymooriA. CRISPR genome editing using computational approaches: A survey.Front. Bioinform.20232100113110.3389/fbinf.2022.100113136710911
     [Google Scholar]
  21. NewbyG.A. LiuD.R. In vivo somatic cell BEand PE.Mol. Ther.202129113107312410.1016/j.ymthe.2021.09.00234509669
     [Google Scholar]
  22. LeeJ. LimK. KimA. MokY.G. ChungE. ChoS.I. LeeJ.M. KimJ.S. Prime editing with genuine Cas9 nickases minimizes unwanted indels.Nat. Commun.2023141178610.1038/s41467‑023‑37507‑836997524
     [Google Scholar]
  23. DebbarmaJ. Recent Tools of Genome Editing and Functional Genomics in Plants: Present and Future Applications on Crop Improvement.CRISPR and Plant Functional Genomics.CRC Press4058
     [Google Scholar]
  24. YarnallM.T.N. IoannidiE.I. Schmitt-UlmsC. KrajeskiR.N. LimJ. VilligerL. ZhouW. JiangK. GarushyantsS.K. RobertsN. ZhangL. VakulskasC.A. WalkerJ.A.II KadinaA.P. ZepedaA.E. HoldenK. MaH. XieJ. GaoG. FoquetL. BialG. DonnellyS.K. MiyataY. RadiloffD.R. HendersonJ.M. UjitaA. AbudayyehO.O. GootenbergJ.S. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases.Nat. Biotechnol.202341450051210.1038/s41587‑022‑01527‑436424489
     [Google Scholar]
  25. WuJ. TangB. TangY. Allele-specific genome targeting in the development of precision medicine.Theranostics20201073118313710.7150/thno.4329832194858
     [Google Scholar]
  26. NickoloffJ.A. SharmaN. AllenC.P. TaylorL. AllenS.J. JaiswalA.S. HromasR. Roles of homologous recombination in response to ionizing radiation-induced DNA damage.Int. J. Radiat. Biol.202399690391410.1080/09553002.2021.195600134283012
     [Google Scholar]
  27. BudzkoL. Hoffa-SobiechK. JackowiakP. FiglerowiczM. Engineered deaminases as a key component of DNA and RNA editing tools.Mol. Ther. Nucleic Acids20233410206210.1016/j.omtn.2023.10206238028200
     [Google Scholar]
  28. Saber SichaniA. A review on advanced CRISPR-based genome-editing tools: BEand PE.Mol. Biotechnol.202365684986010.1007/s12033‑022‑00639‑136547823
     [Google Scholar]
  29. DimitrievskaM. BansalD. VitaleM. StrouboulisJ. MiccioA. NicolaidesK.H. El HossS. ShangarisP. Jacków-MalinowskaJ. Revolutionising healing: Gene Editing’s breakthrough against sickle cell disease.Blood Rev.20246510118510.1016/j.blre.2024.10118538493007
     [Google Scholar]
  30. ChenP.J. LiuD.R. Prime editing for precise and highly versatile genome manipulation.Nat. Rev. Genet.202324316117710.1038/s41576‑022‑00541‑136344749
     [Google Scholar]
  31. SeguraE.E.R. AyoubP.G. HartK.L. KohnD.B. Gene therapy for β-hemoglobinopathies: From discovery to clinical trials.Viruses202315371310.3390/v1503071336992422
     [Google Scholar]
  32. Methods for increasing red blood cell levels and treating ineffective erythropoiesis.Patent CA2942954A12015
  33. An improved fetal hemoglobin for genetic correction of sickle cell disease.Patent CA2938419A12015
  34. Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof.Patent WO2019113149A12018
  35. Crispr/cas-related methods and compositions for treating sickle cell disease.Patent WO2015148863A32015
  36. Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage.Patent EP3310931B12016
  37. Materials and methods for treatment of hemoglobinopathies.Patent WO2019081982A12018
  38. Compositions and methods for non-myeloablative conditioning.Patent WO2018071871A12017
  39. Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa.Patent NCT056815982023
  40. Vitamin D and bisphosphonates in the treatment of sickle cell disease.Patent NCT029721382017
  41. Prevention of morbidity in sickle cell disease pilot phase.Patent NCT004157272006
  42. Ketamine infusion for acute sickle cell crisis in the emergency department (KISS).Patent NCT024172982018
  43. Preventing stroke triggers in children with sickle cell anaemia in Mulago Hospital, Kampala (PREST ): A randomized control trial (PREST).Patent NCT036668062018
  44. A study to investigate the safety, tolerability, and pharmacokinetics of oral GSK4172239D compared with placebo in sickle cell disease participants aged 18 to 50 years.Patent NCT056602652024
  45. Pulmonary ultrasound in the diagnosis of acute thoracic syndrome in vaso-occlusive sickle cell crisis (ECHO-STA).Patent NCT039711362023
  46. Safety and efficacy of CRISPR/ Cas9 mRNA instantaneous gene editing therapy to treat refractory viral keratiti.sPatent NCT045607902022
  47. Study of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells in patients with mesothelin positive multiple solid tumors.Patent NCT035458152020
  48. Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances.Patent NCT031641352017
  49. A safety and efficacy study of TALEN and CRISPR/ Cas9 in the treatment of hpv-related cervical intraepithelial NeoplasiaI.Patent NCT030579122017
/content/journals/cdm/10.2174/0113892002356293250225094826
Loading
Transformative CRISPR-Cas9 Technologies: A Review of Molecular Mechanisms, Precision Editing Techniques, and Clinical Progress in Sickle Cell Disease
Current Drug Metabolism 25, 734 (2024); https://doi.org/10.2174/0113892002356293250225094826
/content/journals/cdm/10.2174/0113892002356293250225094826
/content/journals/cdm/10.2174/0113892002356293250225094826
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): BE; beta globin; clinical trials; CRISPR-Cas9 technology; DNA; patents; PE; Sickle cell disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test